土耳其糖尿病性黄斑水肿患者使用雷珠单抗的真实生活数据：记录连续三年临床优化后的改善情况。
The real life data of ranibizumab use among the diabetic macular edema patients in Turkey: Documenting the improvement with clinical optimization during three consecutive years.
作者信息
Ozkaya Abdullah, Ozveren Mehmet, Demircan Ali
机构信息
Beyoglu Eye Training and Research Hospital, Istanbul, Turkey.
出版信息
Saudi J Ophthalmol. 2018 Jul-Sep;32(3):175-179. doi: 10.1016/j.sjopt.2018.04.005. Epub 2018 Apr 14.
PURPOSE
To report the 12 month real life outcomes of ranibizumab treated diabetic macular edema (DME) patients.
METHODS
Treatment naïve DME patients treated with ranibizumab were included. Patients were divided into three groups according to their hospital admittance years (2013, 2014, and 2015) and were compared in regards to the treatment outcomes.
RESULTS
The mean visual acuity change from baseline to month 12 was not statistically significant in 2013 at month 12. The mean BCVA change from baseline to month 12 was statistically better at month 12 in 2014 and 2015. There was a statistically significant difference among the three groups in regards to both mean visit and injection numbers. The mean visit number in 2013 and 2014 were both lower than 2015. The mean injection number in 2013 was lower than both 2014 and 2015.
CONCLUSIONS
It is effortful to obey the strict follow-up criteria of prospective studies in DME patients on a PRN regimen. However, optimizing the clinical processes of patient management may lead to improved clinical outcomes in real life.
目的
报告雷珠单抗治疗糖尿病性黄斑水肿（DME）患者的12个月真实生活转归。
方法
纳入初治的接受雷珠单抗治疗的DME患者。根据患者入院年份（2013年、2014年和2015年）将患者分为三组，并比较治疗转归。
结果
2013年在第12个月时，从基线到第12个月的平均视力变化无统计学意义。2014年和2015年在第12个月时，从基线到第12个月的平均最佳矫正视力（BCVA）变化在统计学上更好。三组在平均就诊次数和注射次数方面均存在统计学显著差异。2013年和2014年的平均就诊次数均低于2015年。2013年的平均注射次数低于2014年和2015年。
结论
对于采用按需治疗方案的DME患者，要遵循前瞻性研究的严格随访标准是困难的。然而，优化患者管理的临床流程可能会在现实生活中改善临床转归。
Zotero 插件